BIV

BioVie

Stock
Stock
Ticker: BIVI
BIVI

Price

Price

CHART BY

Frequently asked questions

The market capitalization of BioVie is $16.31M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
BioVie's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$3.197. EPS indicates the company's profitability on a per-share basis.
Currently, 1 analysts cover BioVie's stock, with a consensus target price of $5.51. Analyst ratings provide insights into the stock's expected performance.
BioVie's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$22.47M. EBITDA measures the company's overall financial performance.
BioVie has a free cash flow of -$19.02M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
BioVie employs approximately 13 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
The free float of BioVie is 8.03M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$16.31M
EPS (TTM) 
-$3.197
Free Float 
8.03M
EBITDA (TTM) 
-$22.47M
Free Cashflow (TTM) 
-$19.02M

Pricing

52W span
$0.82$3.79

Analyst Ratings

The price target is $5.51 and the stock is covered by 1 analysts.

Buy

1

Hold

0

Sell

0

Information

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders, and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Employees
13
Industries
Biotechnology
Sector
Health Care

Identifier

Primary Ticker
BIVI
Fundamentals & EOD data from FactSet
Join the conversation